D.Western Therapeutics Institute Inc 4576.T-JP:Tokyo Stock Exchange

*Data is delayed | JPY
Last | 3:00 PM JST
208.00quote price arrow up+6.00 (+2.97%)
Volume
553,000
52 week range
183.00 - 313.00
Loading...
  • Open219.00
  • Day High223.00
  • Day Low204.00
  • Prev Close202.00
  • 52 Week High313.00
  • 52 Week High Date11/29/21
  • 52 Week Low183.00
  • 52 Week Low Date02/24/22

Key Stats

  • Market Cap44.75M
  • Shares Out29.36M
  • 10 Day Average Volume33,418.18
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-3.7

KEY STATS

  • Open219.00
  • Day High223.00
  • Day Low204.00
  • Prev Close202.00
  • 52 Week High313.00
  • 52 Week High Date11/29/21
  • 52 Week Low183.00
  • 52 Week Low Date02/24/22
  • Market Cap44.75M
  • Shares Out29.36M
  • 10 Day Average Volume33,418.18
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-3.7

RATIOS/PROFITABILITY

  • EPS (TTM)-22.80
  • P/E (TTM)-9.12
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On D.Western Therapeutics Institute Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors...
Hiroyoshi Hidaka
Chairman of the Board, Chief Scientific Officer, Representative Director
Yuichi Hidaka
President, Representative Director
Address
1-18-11, Nishiki
Nagoya-shi, ACH
460-0003
Japan